BioXcel Therapeutics Inc. (BTAI)

NASDAQ: BTAI · Real-Time Price · USD

1.76

-0.01 (-0.85%)

At close: May 02, 2025, 12:47 PM

BioXcel Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Revenue	2.27M	1.38M	375K	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	2.14M	1.26M	20K	297K	188K	156K	17K	1K	n/a
Gross Profit	123K	120K	355K	-297K	-188K	-156K	-17K	-1K	n/a
Operating Income	-67.25M	-171.78M	-159.65M	-106.94M	-82.3M	-33.6M	-19.96M	-4.54M	-2.12M
Interest Income	2.6M	5.65M	2.53M	4K	155K	633K	n/a	n/a	n/a
Pretax Income	-59.6M	-179.05M	-165.76M	-106.93M	-82.17M	-32.97M	-19.27M	-4.54M	-2.12M
Net Income	-59.6M	-179.05M	-171.85M	-106.63M	-82.01M	-32.34M	-19.27M	-4.54M	-2.12M
Selling & General & Admin	34.49M	83.41M	68.76M	54.23M	24.3M	7.8M	5.4M	1.85M	721K
Research & Development	30.43M	84.33M	91.24M	52.71M	57.99M	25.8M	14.56M	2.69M	1.4M
Other Expenses	2.44M	4.16M	-427K	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	67.37M	171.9M	160M	106.94M	82.3M	33.6M	19.96M	4.54M	2.12M
Interest Expense	15.13M	13.31M	8.21M	40K	27K	n/a	n/a	2K	n/a
Selling & Marketing Expenses	1.39M	19.9M	13.01M	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	69.51M	173.16M	160.02M	106.94M	82.3M	33.6M	19.96M	4.54M	2.12M
Income Tax Expense	n/a	n/a	6.09M	-301K	-161K	-633K	692K	n/a	-2.12M
Shares Outstanding (Basic)	2.54M	29.13M	28.02M	26.37M	21.68M	16.29M	14.57M	15.19M	15.65M
Shares Outstanding (Diluted)	2.54M	29.13M	28.02M	26.37M	21.68M	16.29M	14.57M	15.19M	15.65M
EPS (Basic)	-23.51	-6.15	-6.13	-4.04	-3.78	-1.99	-1.32	-0.3	-0.14
EPS (Diluted)	-23.51	-6.15	-6.13	-4.04	-3.78	-1.99	-1.32	-0.3	-0.14
EBITDA	-44.16M	-165.42M	-157.38M	-107M	-81.98M	-32.81M	-19.25M	-4.54M	n/a
EBIT	-44.47M	-165.74M	-157.54M	-107.29M	-82.17M	-32.97M	-19.27M	-4.54M	-2.12M
Depreciation & Amortization	309K	318K	327K	297K	188K	156K	17K	1K	2.12M